Why is that interesting? Did you try the number? Was he there? Was it real? That is their number and he does work there. So why is it an issue if his profile was just created?
Another Brookstreet Securities Deal that went up in smoke. They always put out announcements saying they will have tons of revenue and maded deals that would bring instant revenue. They obviously were a scam just like Brookstreet.
Conversion price is 7.3 common to one preferred. Not sure why there is such a big spread (arbitrage play) between the price of the preferred and the conversion of 7.3 times the common....which equates to over 20 per preferred (preferred traded for 16.65 yesterday)
I thought this co. Was going chapter 7 or 11. Why is the stock up? Who would buy this pos. The owners are a bunch of ganuvim. If you go online and check out george lintz you will see what i mean. They have great ideas and most likely will use their great ideas to make alot of money for themselves and used us shareholders (bagholders) to get them to this point. Now they go bankrupt and open up under a new (private probably) and make a ton. Something is fishy though as to why it is up.
I agree with everything you said. I have spoken to Mark at Capital in the past. Here are his details. Capital Group Communications, Inc.
Mark Bernhard or Daniel Shea, 415-332-7200. I spoke to him about a month ago and he was waiting to see if the company was able to get financing. It seems it is all down to a question of raising some cash. If they did (no announcements since the ZTS "supposed" close)raise cash, then this is a real winner...my gut however says that since we have not heard a word, that most likely they are still struggling to raise.
I heard they are working on getting financing. I am unsure why they are having such difficulty if supposedly their product is good to go with serious cash flow. Something doesn't add up
Stansberry actually sold at 60 pre-split. I actually think hehas a good newsletter and an overall good record. He lost some good analysts and the replacements have not been as good. I actually gained confidence in his letter, when he originally put the buy on celgene....he disappointed me with his sell recommendation, but as a long time celgene holder (1994)I of course didn't listen to him...although I did buy more when he recommended the buy I believe it was July or August of 2003.
Moe Drabowsky passed away. Todays newspaper had an obituary indicating he was 70 years old and died of Multiple Myeloma. Who knows, if Revlimid or Thalomid would have been available as front line treatments, he might still be alive today. I have no idea if he was treated with Thal or Rev, but at least , starting real soon everyone will be able to get it.
Drabowsky was a picher for 17 seasons spanning three decades (50's-70's)and I believe he won one world series in 1966 with the Baltimore Orioles.
New here, but have invested in Biotech and pharma for many years. I would say that NVS is the best big pharma, and with yesterdays news stock should go to new highs.
Anyone have any thoughts on NVS acquisition startegy?
Currently MM users of Rev are paying 14,000 per month. I assume that is because they need 25MG which today requires a purchase of 2 X 10 MG and 1 X 5MG. Hence the price is significantly greter than for MDS. When Rev is approved for MM, will there be a 25 MG dose (I assume yes) and will the price be 14,000 for the 25 MG dose or will the price be similar to the 5 and 10 MG for MDS? If the price is similar or slightly higher for 25MG, then in fact the sales of Rev per patient will be lower, although there may be many more patients taking the drug.
Thanks and long and strong as always.
I have owned AMCC for about 3 years and it has been a loser so far. It has shown some life lately and I was thinking of averaging. What makes you say it will move.
Rev was approved for 5 and 10 MG while its largest use will be off-label for MM which as I understand it has a dose of 25 MG. Will MM patients be prescribed 3 doses....2 x 10 and 1 x 5? If so, until it is approved for MM the sales to MM patients will be 3 x any expectation. I am sure no analyst has taken that into account.
"surely you must have heard of insurance"
True, but if the recommended doses are either 5 or 10 mg, insurance will certainly not pay for 25mg, even assuming that they will pay for the 5 or 10.
This has been mentioned previously but I don't recall an answer.
When Rev is approved for MDS 5q- the dosing that will be approved will probably be a 5mg and a 10mg pill. However, the dosing for MM appears to be at the 25mg level. For MM Drs. will need to prescribe 2 X 10mg plus a 5mg. Wouldn't the cost be outrageous? Will this prevent Drs. from prescribing to any but the super rich? If as expected the pricing for MDS 5q- will be 30,000-60,000 per year, then MM at this point before its own approval and new dosing sizes would be 90,000 - 180,000 per year.
Ortigia can you help on this.
Do you think Celgene will meet its new revenue expectation target it announced when it released the 3rd quarter figures?